Pneumonitis in advanced non-small cell lung cancer: no interaction between immune checkpoint inhibition and radiation therapy
Journal of Thoracic Disease · 2023-05 · 15 (5) · 2458-2468
DOI: 10.21037/jtd-22-1649 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thoracic Disease, 2023-05. Verfasst von Shane S Neibart und 4 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Radiation pneumonitis and immune-related pneumonitis have been studied independently, but little information has emerged on the interactions between radiation therapy (RT) and immune checkpoint inhibition (ICI). We examine whether RT and ICI are synergistic in causing pneumonitis.
Methods
A retrospective cohort was assembled using the Surveillance, Epidemiology, and End Results-Medicare database, including Medicare beneficiaries diagnosed with American Joint Committee on Cancer 7th ed. (AJCC) stages IIIB-IV NSCLC between 2013-2017. Exposures to RT and ICI were determined by evaluating for treatment within 12 months of diagnosis (RT group and ICI group) and for a second exposure (e.g., ICI after RT) within 3 months after the first exposure (RT + ICI group). Untreated controls were matched to treated patients who were diagnosed in the same three-month window. A validated algorithm for identifying cases of pneumonitis in claims data was used to evaluate for the outcome within 6 months after treatment. The primary outcome was the relative excess risk due to interaction (RERI), a quantitative measure of additive interaction between two treatments.
Results
There were 18,780 patients included in the analysis with 9,345 (49.8%), 7,533 (40.2%), 1,332 (7.1%), and 550 (2.9%) in the control, RT, ICI, and RT + ICI groups, respectively. Relative to controls, the hazards ratios of pneumonitis were 11.5 (95% CI: 7.9 to 17.0), 6.2 (95% CI: 3.8 to 10.3), and 10.7 (95% CI: 6.0 to 19.2) in the RT, ICI, and RT-ICI groups, respectively. The RERIs were -6.1 (95% CI: -13.1 to -0.6, P=0.97) and -4.0 (95% CI: -10.7 to 1.5, P=0.91) in the unadjusted and adjusted analyses, respectively, consistent with no evidence of additive interaction (RERI ≤0) between RT and ICI.
Conclusions
In this study of Medicare beneficiaries with advanced NSCLC, RT and ICI were, at most, additive rather than synergistic in causing pneumonitis. Pneumonitis risk in patients treated with RT and ICI is not more than could be expected from each therapy alone.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
- Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
- Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.
- Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
- Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Zitieren
APA
Neibart, S. S., Malhotra, J., Roy, J. A., Strom, B. L., & Jabbour, S. K. (2023). Pneumonitis in advanced non-small cell lung cancer: no interaction between immune checkpoint inhibition and radiation therapy. Journal of Thoracic Disease, 15(5), 2458-2468. https://doi.org/10.21037/jtd-22-1649
Vancouver
Neibart SS, Malhotra J, Roy JA, Strom BL, Jabbour SK. Pneumonitis in advanced non-small cell lung cancer: no interaction between immune checkpoint inhibition and radiation therapy. Journal of Thoracic Disease. 2023;15(5):2458-2468. doi:10.21037/jtd-22-1649
BibTeX
@article{Neibart2023,
author = {Neibart, Shane S and Malhotra, Jyoti and Roy, Jason A and Strom, Brian L and Jabbour, Salma K},
title = {Pneumonitis in advanced non-small cell lung cancer: no interaction between immune checkpoint inhibition and radiation therapy},
journal = {Journal of Thoracic Disease},
year = {2023},
volume = {15},
number = {5},
pages = {2458--2468},
doi = {10.21037/jtd-22-1649}
}
EUVIMED